Brian McVeigh

Longwood Funds I, II, and III are healthcare venture capital funds that invests in, manages, and builds healthcare companies. Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. Responsible for advising the General Partners and providing advice and counsel as requested by the General Partners in connection with investments… Show more

Longwood Funds I, II, and III are healthcare venture capital funds that invests in, manages, and builds healthcare companies. Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. Responsible for advising the General Partners and providing advice and counsel as requested by the General Partners in connection with investments and other Partnership matters. Show less

Medicxi Ventures is a leading global venture capital firm active in technology and biotechnology venture investing since 1996. Medicxi Ventures I Fund is a $233 million fund that employs Medicxi's "asset centric" model which focuses on investment in companies with just one or two projects, rather than companies with multiple programs. The fund invests in opportunities across Europe primarily, but also across the USA, with assets that have first-in-class or best-in-class mechanisms of action and… Show more

Medicxi Ventures is a leading global venture capital firm active in technology and biotechnology venture investing since 1996. Medicxi Ventures I Fund is a $233 million fund that employs Medicxi's "asset centric" model which focuses on investment in companies with just one or two projects, rather than companies with multiple programs. The fund invests in opportunities across Europe primarily, but also across the USA, with assets that have first-in-class or best-in-class mechanisms of action and target areas of unmet medical need. Show less

Hatteras Venture Partners is a venture capital firm that invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Hatteras Venture Partners Fund V is a $170 million fund that has a similar strategy as Funds III and IV, and also incorporates an allocation of 20% of the for the Hatteras Discovery initiative which is focused on seed-stage companies and projects in the field of human… Show more

Hatteras Venture Partners is a venture capital firm that invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Hatteras Venture Partners Fund V is a $170 million fund that has a similar strategy as Funds III and IV, and also incorporates an allocation of 20% of the for the Hatteras Discovery initiative which is focused on seed-stage companies and projects in the field of human medicine and life sciences. Show less

Phase 1 Ventures is an accelerator that assists innovators at new or recently formed companies. Phase 1 Ventures is owned and managed by the University City Science Center and its partners BioMed Ventures and Wexford Science and Technology

The QED is a multi-institutional proof-of-concept program that provides business development support and funding for academic researchers developing early-stage life science and healthcare IT technologies with high commercial potential.

The GSK Canada Life Sciences Innovation Fund is a new national $50 million fund that significantly advances the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund identifies strategic investment opportunities within Canada's life sciences industry including academic and health institutions, translational research centres and start-up companies.

Hatteras Venture Partners is a venture capital firm that invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Hatteras Venture Partners Fund III is an $83 million fund that can invest in any company in the United States but has an emphasis on investing in companies located in the research-driven regions of North Carolina and the Southeastern United States.

Hatteras Venture Partners is a venture capital firm that invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Hatteras Venture Partners Fund IV is a $125 million fund that has a similar strategy as Fund III, and also incorporates an allocation of 20% of the for the Hatteras Discovery initiative which is focused on seed-stage companies and projects in the field of human medicine… Show more

Hatteras Venture Partners is a venture capital firm that invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Hatteras Venture Partners Fund IV is a $125 million fund that has a similar strategy as Fund III, and also incorporates an allocation of 20% of the for the Hatteras Discovery initiative which is focused on seed-stage companies and projects in the field of human medicine and life sciences. Show less

Index Ventures is a leading global venture capital firm active in technology and biotechnology venture investing since 1996. Index Ventures Life VI Fund is a $200 million fund that employs Index's "asset centric" model which focuses on investment in companies with just one or two projects, rather than companies with multiple programs. The fund invests in opportunities across Europe primarily, but also across the USA, with assets that have first-in-class or best-in-class mechanisms of action… Show more

Index Ventures is a leading global venture capital firm active in technology and biotechnology venture investing since 1996. Index Ventures Life VI Fund is a $200 million fund that employs Index's "asset centric" model which focuses on investment in companies with just one or two projects, rather than companies with multiple programs. The fund invests in opportunities across Europe primarily, but also across the USA, with assets that have first-in-class or best-in-class mechanisms of action and target areas of unmet medical need. Show less

Provide strategic direction and oversight to the leadership team that manages the 300+ member organization. The ECN's mission is to attract, motivate and retain employees early in their career and aid them in reaching their full potential in pursuit of GSK's organizational objectives through mentoring, social networking, and career development opportunities.

Member of the Board of Directors responsible for providing leadership and strategic direction to the management of the Pennsylvania BIO organization. Pennsylvania BIO is the only state-wide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is a global leader in the biosciences by developing a cohesive biotechnology community in Pennsylvania and the mid-Atlantic region that unites the region's biotechnology, pharmaceutical, research, and… Show more

Member of the Board of Directors responsible for providing leadership and strategic direction to the management of the Pennsylvania BIO organization. Pennsylvania BIO is the only state-wide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is a global leader in the biosciences by developing a cohesive biotechnology community in Pennsylvania and the mid-Atlantic region that unites the region's biotechnology, pharmaceutical, research, and financial strengths. The organization facilitates the development of strategic partnerships among state and regional pharmaceutical companies, biotechnology companies, medical device companies and research institutions, and is a public policy leader and the principal public advocate for the bioscience community in Pennsylvania. Show less

Member of the Board of Directors responsible for providing strategic direction and oversight to the CEO and his management team. The Sb1 Federal Credit Union is a full-service, member-oriented financial institution with over $500 million of assets under management, servicing over 100 companies across the country.

Longwood Founders Fund is an $87 million healthcare venture capital fund that founds, manages, and builds healthcare companies. Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors.

Responsibilities included ensuring completion of, and compliance with, National Credit Union Administration Audits, and ruling on credit union membership complaints and appeals. The Sb1 Federal Credit Union is a full-service, member-oriented financial institution with over $500 million of assets under management, servicing over 100 companies across the country.